Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...

Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary ...

Bayer today announced topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic ...

Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies ...

Bayer announces positive results of pivotal phase III QUANTI studies of gadoquatrane, an investigational GBCA for use in magnetic resonance imaging: Berlin Monday, January 13, 202 ...

on MRI (Figure 1). Both immunomicellular approaches were much more successful at increasing the contrast than was using gadolinium alone, which failed to enhance the plaques at all. Figure 1 ...

Medically reviewed by Corinne Savides Happel, MDA contrast dye allergic reaction can occur after a diagnostic imaging test, ...

it also involves the use of chemical agents like gadolinium-based contrast dyes. While these dyes enhance the clarity of MRI images, they can cause toxicity in the body. Recent advances in ...

The study includes patients with severe renal impairment who currently lack an alternative to gadolinium-based contrast MRI. The abstract "Improved detection of focal liver lesions with manganese ...